On Monday, the Special Assistant to the Prime Minister on National Health Services Dr Faisal Sultan informed that the clinical trial data for the phase-3 of a CanSino Bio was compiled.
The interim analysis by the Independent Data Monitoring Committee (IDMC) shows 65.7% efficacy at preventing symptomatic cases and 90.98% at preventing severe disease, he tweeted.
The data comes from a multicountry analysis, which included 30,000 participants & 101 virologically confirmed COVID-19 cases. The IDMC did not report any serious safety concerns for the vaccine.
In the Pakistani subset of the data, the efficacy of the vaccine in preventing symptomatic cases was reported to be at 74.8% and 100% in preventing severe disease.
